Patent ID: 7247610

Claim:
A method of treating cancer comprising administering to a patient in need thereof an inhibitor of the interaction of glutamate with the Kainate receptor complex, wherein the inhibitor is 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline(NBQX), 6,7-dinitro-quinoxaline-2,3-dione (DNQX), 6-nitro-7-cyano-quinoxaline-2,3-dione (CNQX), 6-(1-imidazolyl)-7-nitro-quinoxaline-2,3(1H,4H)-dione (YM90K), [2,3-dioxo-7(1H-imidazol-1-yl)-6-nitro-1,2,3,4-tetrahydro-1-quinoxaliny]-acetic acid monohydrate (YM872), (3RS,4aRS,6RS,8aRS)-6-(2-(1H-tetrazole-5-yl)ethyl)-decahydroiso-quinoline-3-carboxylic acid (LY293558), 9-methyl-amino-6-nitro-hexahydro-benzo(F)quinoxalinedione (PNQX), 8-methyl-5-(4-(N,N-dimethylsulphamoyl)phenyl)-6,7,8,9-tetra-hydro-1H-pyrrolo[3,2h]-isoquinoline-2,3-dione-3-O-(3-hydroxybutyric acid-2-yl)oxime (NS 1209), 6,7-dichloro-2-(1H)-quinolinone-3-phosphonate (S17625-2), [1,2,3,4-tetrahydro-7-morpholinyl-2,3-dioxo-6-(trifluoromethyl)quinoxalin-1-yl]methyl-phosphonate (ZK200775), 1-(aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine (GYKI 52466), γ-D-glutamylaminomethylsulphonate (GAMS), γ-D-glutamylglycine; or a Kainate receptor channel blocker.